drugset / Trial / NCT01743027
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
Timeline
- Start
- 2013-01
- Primary completion
- 2013-07
- Completion
- 2013-07
Publications
- Carr W, Schaeffer J, Donnenfeld E. Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief. Allergy Rhinol (Providence). 2016 Jan;7(2):107-14. doi: 10.2500/ar.2016.7.0158. Epub 2016 Jul 26.
- McLaurin E, Narvekar A, Gomes P, Adewale A, Torkildsen G. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model. Cornea. 2015 Oct;34(10):1245-51. doi: 10.1097/ICO.0000000000000562.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olopatadine | Other / unclassified | 0.1 % | Topical |
| Subject | Olopatadine | Other / unclassified | 0.2 % | Topical |
| Subject | Olopatadine | Other / unclassified | 0.77 % | Topical |